Medical treatment of spasticity

  • D. Boisson
  • M. Eyssette


According to the definition by Lance, spasticity is: “a motor disorder characterized by a velocity-dependent increase of tonic stretch reflexes with exaggerated tendon jerks, resulting from hyperexcitability of the stretch reflex, as one component of the upper motor neuron syndrome”. Spasticity is obviously a heterogenous set of clinical states. As a matter of fact the release of the proprioceptive reflex can be the consequence of a lesion of the corticofugal pathways at any level of Central Nervous System (C.N.S).


Presynaptic Inhibition Dantrolene Sodium Polysynaptic Pathway Skeletal Muscle Sarcoplasmic Reticulum Motor Neuron Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Betz H (1987) Biology and structure of the mamalian glycine receptor. TINS 10:113–117Google Scholar
  2. Costa E, Guidotti A (1979) Molecular mechanisms in the receptor action of benzodiazepines. Annu Rev Pharmacol Toxicol 19:531–545PubMedCrossRefGoogle Scholar
  3. Curtis DR, Lodge D, Borstein JC, Peet MJ (1981) Selective effect of (—) Baclofen on spinal synaptic transmission in the cat. Exp Brain Res 42:158–170PubMedCrossRefGoogle Scholar
  4. Corston RN, Johnson F, Godwin-Austen RB (1981) The assessment of drug treatment of spastic gait. J Neurol Neurosurg Psychiatry 44:1035–1039PubMedCrossRefGoogle Scholar
  5. Davidoff A (1985) Antispasticity drugs: mechanisms of action. Ann Neurol 17:107–116PubMedCrossRefGoogle Scholar
  6. Davies J, Quinlan JE (1985) Selective inhibition of responses of feline dorsal horn neurones to noxious cutaneous stimuli by Tizanidine (DS103–282) and Noradrenaline: involvement of alpha 2-adrenoceptors. Neuroscience 16(3):673–682PubMedCrossRefGoogle Scholar
  7. Delwaide JP, Dresse A (1984) Les myorelaxants. Sem Hop Paris 60(40):2897–2929Google Scholar
  8. Delwaide JP (1985) Electrophysiological analysis of the mode of action of muscle relaxants in spasticity. Ann Neurol 17:90–5PubMedCrossRefGoogle Scholar
  9. Duncan GW, Shahani BT, Young RR (1976) An evaluation of baclofen treatment for certain symptoms in patients with spinal cord lesions: a double-blind cross-over study. Neurology 26:441–6PubMedCrossRefGoogle Scholar
  10. Eyssette M, Rohmer F, Serratrice G, Warter JM, Boisson D (1988) Multi-centrer, double-blind trial of a novel antispastic agent, Tizanidine, in spasticity associated with multiple sclerosis. Curr Med Res Opin 10(10)Google Scholar
  11. Gonsette RE, Desmet Y, Demonty L (1984) Tizanidine, a new antispastic agent: 6 years clinical experience in 152 MS sclerosis. MTD Press Ltd, Lancaster Boston The Hauge Dordrecht, pp 219–225Google Scholar
  12. Hassan N, McLellan DL (1980) Double-blind comparison of single doses of DS-103–282, Baclofen and placebo for suppression of spasticity. J Neurol Neurosurg Psychiatry 43:1132–6PubMedCrossRefGoogle Scholar
  13. Hughes JT, Phil D (1989) The new neuro-anatomy of the spinal cord. Paraplegia 27:90–98PubMedCrossRefGoogle Scholar
  14. Joynt RL (1976) Dantrolene sodium: long-term effects in patients with muscle spasticity. Arch Phys Med Rehabil 57:212–217PubMedGoogle Scholar
  15. Katz RT (1988) Management of spasticity. Am J Phys Med Rehabil 67(3)Google Scholar
  16. Knutsson E, Martensson A, Gransberg L (1982) Antiparetic and antispastic effects induced by Tizanidine in patients with spastic paresis. J Neurol Sci 53:187–204PubMedCrossRefGoogle Scholar
  17. Lance JW (1980) Pathophysiology of spasticity and clinical experience with Baclofen. In: Feldman RG, Young RR, Koella WP (eds) Spasticity: disordered motor control. Year book, Chicago, pp 185–203Google Scholar
  18. Lossius R, Dietrichson P, Lunde PKM (1980) Effect of Diazepam and desmethyldiazepan in spasticity and rigidity. A quantitative study of reflexes and plasma concentrations. Acta Neurol Scand 61:378–388PubMedCrossRefGoogle Scholar
  19. Meyler WJ, Bakker H, Kok JJ, Agoston S, Wesseling H (1981) The effect of Dantrolene sodium in relation to blood levels in spastic patients after prolonged administration. J Neurol Neurosurg Psychiatry 44:334–339PubMedCrossRefGoogle Scholar
  20. Nabeshima T, Matsuno K, Sugimoto A, Kameyama T (1987) Antinociceptive activity induced by Tizanidine and Alpha-2 adrenoreceptors. Neuropharmacology 26:1453–1455PubMedCrossRefGoogle Scholar
  21. Newman PM, Nogues M, Newman PK, Weightman D, Hudgson P (1982) Tizanidine in the treatment of spasticity. Eur J Clin Pharmacol 23:31–35PubMedCrossRefGoogle Scholar
  22. Pinder RM, Brogden RN, Speight TM, Avery GS (1977) Dantrolene sodium: a review of its pharmacological properties and therapeutic efficacy in spasticity. Drugs 13:3–23PubMedCrossRefGoogle Scholar
  23. van Winkle WB (1976) Calcium release from skeletal muscle sarcoplasmic reticulum: site of action of dantrolene sodium? Science 193:1130–1131PubMedCrossRefGoogle Scholar
  24. Wilkinson SP, Portman B, Williams R (1979) Hepatitis from dantrolene sodium. Gut 20:33–36PubMedCrossRefGoogle Scholar
  25. Wilson PR, Yaksh TL (1978) Baclofen is antinociceptive in the spinal intrathecal space of animals. Eur J Pharmacol 51:323–330PubMedCrossRefGoogle Scholar
  26. Young RR, Delwaide PJ (1981) Drug therapy in spasticity. N Engl J Med 304:28–33, 96–99Google Scholar

Copyright information

© Springer-Verlag Wien 1991

Authors and Affiliations

  • D. Boisson
    • 1
  • M. Eyssette
    • 2
  1. 1.Hôpital NeurologiqueLyonFrance
  2. 2.Hôpital Henry GabrielleSaint Genis LavalFrance

Personalised recommendations